Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis

被引:450
作者
Agrawal, S
Anderson, P
Durbeej, M
van Rooijen, N
Ivars, F
Opdenakker, G
Sorokin, LM [1 ]
机构
[1] Lund Univ, S-22185 Lund, Sweden
[2] Free Univ Amsterdam, NL-1081 BT Amsterdam, Netherlands
[3] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
[4] Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany
关键词
D O I
10.1084/jem.20051342
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The endothelial cell monolayer of cerebral vessels and its basement membrane ( BM) are the leptomeningeal cells, and their associated parenchymal BM, all of which contribute to establishment of the blood-brain barrier (BBB). As a consequence of this unique structure, leukocyte penetration of cerebral vessels is a multistep event. In mouse experimental autoimmune encephalomyelitis (EAE), a widely used central nervous system inflammatory model, leukocytes first penetrate the endothelial cell monolayer and underlying BM using integrin beta 1-mediated processes, but mechanisms used to penetrate the second barrier defined by the parenchymal BM and glia limitans remain uninvestigated. We show here that macrophage-derived gelatinase (matrix metalloproteinase [MMP]-2 and MMP-9) activity is crucial for leukocyte penetration of the parenchymal BM. Dystroglycan, a transmembrane receptor that anchors astrocyte endfeet to the parenchymal BM via high affinity interactions with laminins 1 and 2, perlecan and agrin, is identified as a specific substrate of MMP-2 and MMP-9. Ablation of both MMP-2 and MMP-9 in double knockout mice confers resistance to EAE by inhibiting dystroglycan cleavage and preventing leukocyte infiltration. This is the first description of selective in situ proteolytic damage of a BBB-specific molecule at sites of leukocyte infiltration.
引用
收藏
页码:1007 / 1019
页数:13
相关论文
共 48 条
[1]   Defining antigen-dependent stages of T cell migration from the blood to the central nervous system parenchyma [J].
Archambault, AS ;
Sim, J ;
Gimenez, MAT ;
Russell, JH .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (04) :1076-1085
[2]   Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection [J].
Campbell, LG ;
Ramachandran, S ;
Liu, W ;
Shipley, JM ;
Itohara, S ;
Rogers, JG ;
Moazami, N ;
Senior, RM ;
Jaramillo, A .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (03) :517-528
[3]   Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions [J].
Dubois, B ;
Masure, S ;
Hurtenbach, U ;
Paemen, L ;
Heremans, H ;
van den Oord, J ;
Sciot, R ;
Meinhardt, T ;
Hämmerling, G ;
Opdenakker, G ;
Arnold, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (11) :1507-1515
[4]   Dystroglycan in development and disease [J].
Durbeej, M ;
Henry, MD ;
Campbell, KP .
CURRENT OPINION IN CELL BIOLOGY, 1998, 10 (05) :594-601
[5]  
ENGELHARDT B, 1997, ADHESION MOL CHEMOKI, P173
[6]   MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity [J].
Esparza, J ;
Kruse, M ;
Lee, J ;
Michaud, M ;
Madri, JA .
FASEB JOURNAL, 2004, 18 (14) :1682-1691
[7]   Expression of mouse agrin in normal, denervated and dystrophic muscle [J].
Eusebio, A ;
Oliveri, F ;
Barzaghi, P ;
Ruegg, MA .
NEUROMUSCULAR DISORDERS, 2003, 13 (05) :408-415
[8]   Inhibition of obliterative airway disease development in murine tracheal allografts by matrix metalloproteinase-9 deficiency [J].
Fernández, FG ;
Campbell, LG ;
Liu, W ;
Shipley, JM ;
Itohara, S ;
Patterson, GA ;
Senior, RM ;
Mohanakumar, T ;
Jaramillo, A .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (04) :671-683
[9]   Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis [J].
Flügel, A ;
Berkowicz, T ;
Ritter, T ;
Labeur, M ;
Jenne, DE ;
Li, ZX ;
Ellwart, JW ;
Willem, M ;
Lassmann, H ;
Wekerle, H .
IMMUNITY, 2001, 14 (05) :547-560
[10]  
FORD AL, 1995, J IMMUNOL, V154, P4309